De Marco Raffaele, Pesaresi Alessandro, Bianconi Andrea, Zotta Michela, Deandreis Désirée, Morana Giovanni, Zeppa Pietro, Melcarne Antonio, Garbossa Diego, Cofano Fabio
Neurosurgery Unit, Department of Neuroscience "Rita Levi Montalcini", "Città della Salute e della Scienza" University Hospital, University of Turin, 10124 Turin, Italy.
Nuclear Medicine Division, Department of Nuclear Medicine, "Città della Salute e della Scienza" University Hospital, University of Turin, 10124 Turin, Italy.
Cancers (Basel). 2022 Dec 23;15(1):90. doi: 10.3390/cancers15010090.
Amino acid PET imaging has been used for a few years in the clinical and surgical management of gliomas with satisfactory results in diagnosis and grading for surgical and radiotherapy planning and to differentiate recurrences. Biological tumor volume (BTV) provides more meaningful information than standard MR imaging alone and often exceeds the boundary of the contrast-enhanced nodule seen in MRI. Since a gross total resection reflects the resection of the contrast-enhanced nodule and the majority of recurrences are at a tumor's margins, an integration of PET imaging during resection could increase PFS and OS. A systematic review of the literature searching for "PET" [All fields] AND "glioma" [All fields] AND "resection" [All fields] was performed in order to investigate the diffusion of integration of PET imaging in surgical practice. Integration in a neuronavigation system and intraoperative use of PET imaging in the primary diagnosis of adult high-grade gliomas were among the criteria for article selection. Only one study has satisfied the inclusion criteria, and a few more (13) have declared to use multimodal imaging techniques with the integration of PET imaging to intentionally perform a biopsy of the PET uptake area. Despite few pieces of evidence, targeting a biologically active area in addition to other tools, which can help intraoperatively the neurosurgeon to increase the amount of resected tumor, has the potential to provide incremental and complementary information in the management of brain gliomas. Since supramaximal resection based on the extent of MRI FLAIR hyperintensity resulted in an advantage in terms of PFS and OS, PET-based biological tumor volume, avoiding new neurological deficits, deserves further investigation.
氨基酸正电子发射断层扫描(PET)成像已在神经胶质瘤的临床和外科治疗中应用数年,在诊断、分级以制定手术和放疗计划以及鉴别复发方面取得了令人满意的结果。生物肿瘤体积(BTV)比单纯的标准磁共振成像(MR)能提供更有意义的信息,且常常超出MRI中可见的强化结节边界。由于根治性全切除反映的是强化结节的切除,而大多数复发位于肿瘤边缘,因此在切除过程中整合PET成像可能会提高无进展生存期(PFS)和总生存期(OS)。为了研究PET成像整合在外科实践中的普及情况,我们对文献进行了系统回顾,检索词为“PET”[所有字段]、“神经胶质瘤”[所有字段]和“切除”[所有字段]。文章选择标准包括在神经导航系统中的整合以及PET成像在成人高级别神经胶质瘤初诊中的术中应用。只有一项研究符合纳入标准,另外还有13项研究宣称使用了整合PET成像的多模态成像技术,以有意对PET摄取区域进行活检。尽管证据有限,但除了其他工具外,针对生物活性区域有助于神经外科医生在术中增加肿瘤切除量,有可能在脑胶质瘤的治疗中提供额外的补充信息。由于基于MRI液体衰减反转恢复序列(FLAIR)高信号范围的超根治性切除在PFS和OS方面具有优势,基于PET的生物肿瘤体积在避免新的神经功能缺损方面值得进一步研究。